INTRODUCTION
============

Persistent Human Papillomavirus (HPV) infection is the causative agent of benign and malignant squamous epithelial lesions that can lead to cervical cancer \[[@R1]\], and HPV 16 and 18 are responsible for 70% of cases of this cancer worldwide \[[@R2]\]. With the implementation of prophylactic vaccines against HPV 16 and 18 (Cervarix^®^- GlaxoSmithKline, Rixensart, Belgium) or HPV 6, 11, 16, and 18 (Gardasil^®^- Sanofi Pasteur MSD, Lyon, France), a major reduction in the incidence of cervical cancer is expected. Consequently, effective protection against HPV 16 and 18 and possible cross-protection against other genotypes will modify the prevalence of HPV genotypes in vaccinated populations \[[@R3],[@R4]\]. However, HPV testing will still be required to follow-up lesions caused by genotypes not included in the vaccines and to study their involvement in cervical lesions. HPV geno-typing also remains necessary for the adequate screening of non-vaccinated populations and in epidemiologic studies.

HPV testing is mainly performed using dry swabs, liquid-based cytologies, or formalin-fixed paraffin-embedded (FFPE) biopsies as biological material. FFPE specimens are taken from selected target regions of the cervical epithelium, allowing detected HPV genotypes to be linked to specific lesions. Hence, sensitive viral detection in FFPE biopsies is important for the screening of cervical cancer and precursor lesions and for epidemiology and vaccinology studies \[[@R5]\]. However, HPV testing is known to perform poorly in FFPE samples due to partial DNA fragmentation in the embedded tissue \[[@R6]\], resulting in lower HPV detection rates and impairing the identification of multiple infections in comparison to fresh cervical smears.

The HPV Direct Flow CHIP test (Master Diagnóstica, Granada, Spain) was recently launched onto the market as a new system for rapid and sensitive HPV genotyping. This PCR-based method is able to identify 36 HPV genotypes: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44/55, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 84, and 89. The specific formulation of the PCR mix and the polymerase in the kit allow the PCR to be completed within 60 min. It includes the amplification of a 268 bp fragment of the human beta-globin gene (internal control) and a 150 bp fragment of the HPV L1 region (GP5+/GP6+). The reverse dot blot hybridization and read-out of the results are then performed automatically in the e-BRID System™ (Master Diagnóstica, Granada, Spain), which takes 90 min to complete a set of 15 samples. Although purified DNA can be the input material for the amplification, this system can also perform so-called Direct PCR by using crude cell extracts from cervical swabs, liquid-based cytologies, or FFPE sections as amplification templates, precluding the need for previous DNA purification.

The analytical sensitivity and specificity of the HPV Direct Flow CHIP system were certified after enrolment in the 2011 WHO Proficiency Panel (manuscript in preparation); the results of the quality program demonstrated that the kit can specifically detect 5 IU of HPV 16 and 18 and 50 GE of HPV 6, 11, 31, 33, 35, 39, 45, 51, 52, 58, 59, 66, 68a and 68b in single and multiple infection settings. The performance of HPV Direct Flow CHIP in cytological samples was found to be highly similar to that of the Linear Array Genotyping Test (Roche Molecular Systems, Alameda, CA, USA), Hybrid Capture 2 (Digene Corp., Gaithersburg, MD, USA), and CLART HPV2 (Genomica, Tres Cantos, Madrid, Spain) commercial assays, by Direct PCR (using crude cell extracts) \[[@R7]\]. In addition, a high agreement was observed among the results of HPV Direct Flow CHIP, Linear Array Genotyping Test, and Direct Sequencing when purified DNA was used as amplification template (submitted for publication). However, the efficacy of HPV detection in purified DNA from FFPE samples was found to be significantly higher with HPV Direct Flow CHIP than with CLART HPV2 in a small pilot study \[[@R7]\].

In order to further characterize the HPV Direct Flow CHIP system, the present study evaluated its performance in cervical FFPE biopsies. Paired samples for Direct PCR and Conventional PCR from FFPE samples were used for the HPV Direct Flow CHIP testing, and the results of the two protocols were compared. Samples (n=99) were collected from patients with an abnormal cytology or under follow-up for cervical lesion between 2010 and 2013 in the Elda General Hospital (Alicante, Spain) and Ruber Clinic (Madrid, Spain). The patients signed their informed consent for all specimens, and the study procedures were approved by the clinical research ethics committees of the hospitals.

The biopsies were fixed for 48 h in formalin and embedded in paraffin, and FFPE samples were then sectioned. Several serial sections were taken from each biopsy, the two outer sections were stained with hematoxylin-eosin, examined under the microscope, and classified as: normal, mild dysplasia/cervical intraepithelial neoplasia (CIN) grade 1 (CIN1), moderate dysplasia/CIN grade 2 (CIN2), severe dysplasia/CIN grade 3 (CIN3), or cervical carcinoma. The inner sections were used for HPV detection by using the HPV Direct Flow CHIP with two different protocols (Direct and Conventional PCR). For the Direct PCR, one to three sections were digested in 60 µL Lysis Buffer (Master Diagnóstica, Granada, Spain) and 1.5 µL of DNA Release (Master Diagnóstica, Granada, Spain) for 30 min at 60ºC in a MJ Mini™ Thermal Cycler (Bio-Rad, Hercules, CA, USA), followed by inactivation at 98ºC for 10 min. Six microliters of the extracts obtained were added to 53 µL of the PCR mix and 1 µL of DNA polymerase supplied in the kit (Master Diagnóstica, Granada, Spain). For the Conventional PCR, the purified DNA to be used as amplification template was automatically extracted from other one to three inner sections, using the Maxwell^®^ 16 system with Maxwell^®^ 16 FFPE Plus Lev DNA Purification Kit (Promega, Madison, Wisconsin, USA), and eluted in 30-50 microliters of TE buffer following the manufacturer´s instructions. Then, 6 µL of the corresponding template were added to 53 µL of PCR mix and 1 µL of DNA polymerase. The cycling conditions in the MJ Mini™ Thermal Cycler, identical for both protocols, were: denaturation at 98°C for 5 min; 5 cycles of denaturation at 98°C for 5 s, annealing at 42°C for 5 s, and elongation at 72°C for 10 s; 45 cycles of denaturation at 98°C for 5 s, annealing at 60°C for 5 s, and elongation at 72°C for 10 s; and final elongation at 72°C for 1 min. Amplicons were denatured for 5 min at 95ºC and hybridized in the e-BRID System™ (Master Diagnóstica, Granada, Spain) as previously described \[[@R7]\]. The results obtained with the two protocols were compared, obtaining the overall agreement, positive agreement, and Cohen´s Kappa coefficient and applying the McNemar chi-square test.

The study population (n= 99, mean age 33.86 yrs, standard deviation of 9.7 yrs) was histologically distributed as follows: 15.2% normal (n=15), 52.5% CIN1 (n=52), 20.2% CIN2 (n=20), 7.1% CIN3 (n=7), and 5.1% carcinoma (n=5). All samples tested were positive for the human beta-globin internal control in both protocols and were therefore considered valid. The agreement between the two methods for overall HPV positivity was 98.98% (Direct PCR: 93 samples HPV-positive and 5 HPV-negative; Conventional PCR: 94 samples HPV-positive and 4 HPV-negative). The overall positive agreement between the methods was very high (Table **[1](#T1){ref-type="table"}**), and although a slightly higher rate of HPV detection was observed with Conventional PCR, the difference was not statistically significant. Likewise, as shown in Table **[2](#T2){ref-type="table"}**, no significant difference was found in the detection of multiple-infection cases (Direct PCR: 66 cases, Conventional PCR: 71 cases; Kappa index = 0.49). Study of the genotype-specific agreement indicated a high concordance between the protocols in the detection of carcinogenic genotypes, with Kappa indexes ranging from moderate to perfect (Table **[3](#T3){ref-type="table"}**). The most prevalent genotypes were HPV 16, 6, and 18, although their prevalence varied according to the lesion grade, ranging from 58.7%, 28.6% and 12.7% (Direct PCR) or 54%, 33.3% and 11.1% (Conventional PCR), respectively, in \<CIN2 patients, to 65.6%, 15.6% and 25% (Direct PCR) or 56.3%, 25% and 28.1% (Conventional PCR) in ≥CIN2 patients. Slightly higher detection rates were obtained with Direct (*versus* Conventional) PCR for HPV 16, 43 and 52 and with Conventional (*versus* Direct) PCR for HPV 6, 11 and 61. The small non-significant differences between the two protocols may be attributable to a lower amplification yield for the non-purified templates, probably due to the presence of PCR inhibitors from cell lysates in the Direct PCR mixture. However, the agreement between the protocols was very good (Table **[1](#T1){ref-type="table"}**), especially in ≥CIN2 patients (100%), suggesting that the results are more similar with greater disease severity, as previously observed for the HPV Direct Flow CHIP system \[[@R7]\]. Analysis of the clinical performance of HPV Direct Flow CHIP showed the same sensitivity value (100%, CI 95%; 89.28-100) and negative predictive value (100%) for both protocols. The positive predictive value was 34.04% for Direct PCR and 33.68% for Conventional PCR.

Unlike other systems, such as the Linear Array Genotyping Test, in which the internal control amplified fragment is smaller than the HPV amplicon (268 bp versus 450 bp), the HPV Direct Flow CHIP test is based on the amplification of a beta-globin control fragment of 268 bp and an HPV fragment of approximately 150 bp. Given that the DNA tends to be partially fragmented in FFPE samples, the correct amplification of this internal control fragment demonstrates the viability of the sample to amplify a 150 bp fragment of the HPV genome with the HPV Direct Flow CHIP system. This PCR formulation reduces the likelihood of a false negative result, because the HPV will be amplified more efficiently than the beta-globin fragment; therefore, a positive signal for beta-globin and negative signal for HPV should indicate a true HPV-negative sample. Besides the design of the PCR mix, the high sensitivity of the test in FFPE samples can be attributed to the small size of the HPV amplicons. Differences in sensitivity rates as a function of amplicon size were previously reported for other systems based on the amplification of small viral sequences. Thus, the INNO-LiPA assay (Innogenetics, Ghent, Belgium) which includes SPF10 primers targeting a small viral region of 65 bp, proved less prone to degradation and more sensitive to detect HPV in FFPE samples in comparison to systems with larger amplicon sizes, such as HPV2 CLART (HPV amplicon size: 450 bp) \[[@R8],[@R9]\] and Linear Array Genotyping Test (HPV amplicon size: 450 bp) \[[@R10]\]. Further research is warranted to compare the performance of the HPV Direct Flow CHIP in FFPE samples with that of INNO-LiPA and other highly sensitive techniques.

Finally, the use of different commercial kits for DNA purification can produce changes in the rates of HPV detection due to DNA degradation and cross-linkage, leading to low intra-assay reproducibility, as reported for the Linear Array Genotyping Test and INNO-LiPA methods \[[@R11]\]. In the present study, the sensitivity of the HPV Direct Flow CHIP system did not vary between the use of DNA purified by means of the Maxwell^®^ 16 FFPE Plus Lev DNA Purification Kit and the use of non-purified material.

In conclusion, pair-wise comparisons demonstrated a high agreement between Direct PCR and Conventional PCR protocols in the detection of HPV in FFPE samples with the HPV Direct Flow CHIP, which demonstrated a very high sensitivity in this type of sample. A larger number of genotypes were detected in multiple-infection by Conventional *versus* Direct PCR, but the clinical sensitivity and specificity values were similar between the two approaches. HPV detection and genotyping is crucial in FFPE specimens, especially in the follow-up of patients with cervical lesions. The results from this study validate a new system that represents a powerful, simple and low-cost assay for HPV analysis in such samples.
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FFPE

:    = Formalin-fixed paraffin-embedded

CIN1

:    = CIN- grade 1 (cervical intraepithelial neoplasia)

CIN2

:    = CIN grade 2 (moderate dysplasia)

CIN3

:    = CIN grade 3 (severe dysplasia)
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###### 

Overall HPV Detection by HPV Direct Flow CHIP Using Direct PCR and Conventional PCR Protocols

                      Direct PCR/ Conventional PCR   N of Samples   Agreement   Positive Agreement   Kappa Index (95% CI)   McNemar p-Value
  ------------------- ------------------------------ -------------- ----------- -------------------- ---------------------- -----------------
  \<CIN2 (N=67)       Positive/positive              62             98.51       92.54                0.88 (0.65-1)          1
   Concordant         23                                                                                                    
   Compatible         39                                                                                                    
  Positive/negative   0                                                                                                     
  Negative/positive   1                                                                                                     
  Negative/negative   4                                                                                                     
  ≥CIN2 (N=32)        Positive/positive              32             100         100                  \-                     \-
   Concordant         15                                                                                                    
   Compatible         17                                                                                                    
  Positive/negative   0                                                                                                     
  Negative/positive   0                                                                                                     
  Negative/negative   0                                                                                                     

Concordant = exactly the same genotype(s) detected by both methods; Compatible = at least one genotype detected by both methods. N = number. CI = confidence interval.

###### 

Detection of Multiple Infections by HPV Direct Flow CHIP Using Direct PCR and Conventional PCR Protocols

  Genotypes Detected by Conventional PCR (N)   Genotypes Detected by Direct PCR (N)   Kappa Index (95% CI)   Mc Nemar p-Value                                
  -------------------------------------------- -------------------------------------- ---------------------- ------------------ ---- ---- ------------------ -------
  None                                         4                                      0                      0                  0    0    0.49 (0.37-0.62)   0.289
  One                                          1                                      17                     4                  1    0                       
  Two                                          0                                      11                     13                 6    2                       
  Three                                        0                                      0                      5                  10   1                       
  Four or more                                 0                                      0                      6                  1    17                      

N: number. CI: confidence interval.

###### 

Comparison of Genotype Detection by Direct PCR and Conventional PCR: Overall Agreement, Positive Agreement, Kappa Index, and McNemar Test

  HPV Genotype   Direct PCR/ Conventional PCR   Agreement   Positive Agreement   Kappa   McNemar p-Value                   
  -------------- ------------------------------ ----------- -------------------- ------- ----------------- ------- ------- -------
  6              15                             7           11                   62      81.05             15.79   0.499   0.481
  11             8                              4           8                    75      87.37             8.42    0.499   0.388
  16             52                             6           1                    36      92.63             54.74   0.849   0.125
  18             16                             0           1                    78      98.95             16.84   0.963   1
  26             0                              1           0                    94      98.95             0.00    \-      \-
  31             6                              3           2                    84      94.74             6.32    0.677   1
  33             5                              0           3                    87      96.84             5.26    0.753   0.25
  35             3                              1           1                    90      97.89             3.16    0.739   1
  39             7                              1           2                    85      96.84             7.37    0.806   1
  40             0                              1           1                    93      97.89             0.00    \-      \-
  42             12                             0           1                    82      98.95             12.63   0.954   1
  43             5                              4           2                    84      93.68             5.26    0.591   0.687
  44/55          2                              0           1                    92      98.95             2.11    0.795   1
  45             4                              0           2                    89      97.89             4.21    0.789   0.5
  51             7                              1           0                    87      98.95             7.37    0.928   1
  52             8                              4           0                    83      95.79             8.42    0.778   0.125
  53             4                              3           3                    85      93.68             4.21    0.537   1
  54             6                              0           2                    87      97.89             6.32    0.846   0.5
  56             4                              1           1                    89      97.89             4.21    0.789   1
  58             5                              1           1                    88      97.89             5.26    0.822   1
  59             1                              2           2                    90      95.79             1.05    0.312   1
  61             1                              0           3                    91      96.84             1.05    0.390   0.25
  62/81          7                              2           2                    84      95.79             7.37    0.755   1
  66             3                              3           3                    86      93.68             3.16    0.466   1
  67             1                              0           2                    92      97.89             1.05    0.492   0.5
  68             2                              2           1                    90      96.84             2.11    0.555   1
  69             1                              0           0                    94      100.00            1.05    1       1
  70             3                              1           2                    89      96.84             3.16    0.650   1
  72             0                              1           1                    93      97.89             0.00    \-      \-
  73             2                              0           2                    91      97.89             2.11    0.657   0.5
  82             3                              2           1                    89      96.84             3.16    0.65    1
  84             2                              1           0                    92      98.95             2.11    0.795   1
  89             3                              0           0                    92      100.00            3.16    1       1

N: number. CI: confidence interval. Calculations were done considering the 95 HPV samples found to be HPV-positive with at least one of the protocols.
